Experimental psychiatric illness and drug abuse models: From human to animal, an overview

Methods in Molecular Biology

Volumn 829, Issue , 2012, Pages 31-48

  Edwards, Scott ^a   Koob, George F ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

Animal model; Anxiety; Depression; Drug addiction; Preclinical model; Psychiatric disorders; Stress

Indexed keywords

ADDICTION; ANIMAL; ANXIETY; DEPRESSION; DISEASE MODEL; HUMAN; MENTAL DISEASE; PSYCHOLOGICAL ASPECT; REVIEW;

ANIMALS; ANXIETY; DEPRESSION; DISEASE MODELS, ANIMAL; HUMANS; MENTAL DISORDERS; SUBSTANCE-RELATED DISORDERS;

ANIMALIA;

EID: 84856329915     PISSN: 10643745     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-61779-458-2_2     Document Type: Review

References (99)

1. Edwards, S.; Koob, G. F. (2010) Neurobiology of dysregulated motivational systems in drug addiction, Future Neurol 5, 393-401.
2. Covington, H. E.; 3rd, Vialou, V.; Nestler, E. J. (2010) From synapse to nucleus: novel targets for treating depression, Neuropharmacology 58, 683-693.
3. McKinney, W. (1989) Basis of development of animal models in psychiatry: an overview. in Animal models of depression (Koob, G. F.; Ehlers CL, Kupfer DJ, Ed.), pp 3-17, Birkhauser, Boston, Basel.
4. Adriani, W.; Granstrem, O.; Macri, S.; Izykenova, G.; Dambinova, S.; Laviola, G. (2004) Behavioral and neurochemical vulnerability during adolescence in mice: studies with nicotine, Neuropsychopharmacology 29, 869-878. (Pubitemid 38526787)
5. Brown, S. A.; Tapert, S. F. (2004) Adolescence and the trajectory of alcohol use: basic to clinical studies, Ann N Y Acad Sci 1021, 234-244. (Pubitemid 38879629)
6. ODell, L. E. (2009) A psychobiological framework of the substrates that mediate nicotine use during adolescence, Neuropharmacology 56 Suppl 1, 263-278.
7. Schramm-Sapyta, N. L.; Walker, Q. D.; Caster, J. M.; Levin, E. D.; Kuhn, C. M. (2009) Are adolescents more vulnerable to drug addiction than adults? Evidence from animal models, Psychopharmacology (Berl) 206, 1-21.
8. Palanza, P. (2001) Animal models of anxiety and depression: how are females different?, Neurosci Biobehav Rev 25, 219-233. (Pubitemid 32506875)
9. Fattore, L.; Altea, S.; Fratta, W. (2008) Sex differences in drug addiction: a review of animal and human studies, Womens Health (Lond Engl) 4, 51-65.
10. McClung, C. A. (2007) Circadian genes, rhythms and the biology of mood disorders, Pharmacol Ther 114, 222-232. (Pubitemid 46561535)
11. Falcon, E.; McClung, C. A. (2009) A role for the circadian genes in drug addiction, Neuropharmacology 56 Suppl 1, 91-96.
12. Ebel, R. (1961) Must all tests be valid?, American Psychologist 16, 640-647.
13. Sayette, M. A.; Shiffman, S.; Tiffany, S. T.; Niaura, R. S.; Martin, C. S.; Shadel, W. G. (2000) The measurement of drug craving, Addiction 95 Suppl 2, S189-210. (Pubitemid 30650382)
14. Cronbach, L. J.; Meehl, P. E. (1955) Construct validity in psychological tests, Psychol Bull 52, 281-302.
15. Katz, J. L.; Higgins, S. T. (2003) The validity of the reinstatement model of craving and relapse to drug use, Psychopharmacology (Berl) 168, 21-30. (Pubitemid 36851159)
16. McKinney, W. (1988) Models of Mental Disorders: A New Comparative Psychiatry, Plenum, New York.
17. MA Geyer, A. M. (1995) Animal models of psychiatric disorders, in Psychopharmacology: The Fourth Generation of Progress (FE Bloom, D. K.; Ed.), pp 787-798 Raven Press, New York.
18. Willner, P. (1984) The validity of animal models of depression, Psychopharmacology (Berl) 83, 1-16. (Pubitemid 14141479)
19. Matthysse, S. (1986) Animal models in psychiatric research, Prog Brain Res 65, 259-270. (Pubitemid 17150944)
20. Ellenbroek, B. A.; Cools, A. R. (2000) Animal models for the negative symptoms of schizophrenia, Behav Pharmacol 11, 223-233. (Pubitemid 30449754)
21. Markou, A.; Koob, G. F. (1992) Construct validity of a self-stimulation threshold paradigm: effects of reward and performance manipulations, Physiol Behav 51, 111-119.
22. Gilpin, N. W.; Koob, G. F. (2008) Neurobiology of Alcohol Dependence: Focus on Motivational Mechanisms, Alcohol Res Health 31, 185-195.
23. Association, A. P. (1994) Diagnostic and Statistical Manual of Mental Disorders, 4 ed.
24. Koob, G. F.; Le Moal, M. (2001) Drug addiction, dysregulation of reward, and allostasis, Neuropsychopharmacology 24, 97-129.
25. Bindra (1976) A Theory of Intelligent Behavior, Wiley, New York.
26. Koob, G. F. (2008) A role for brain stress systems in addiction, Neuron 59, 11-34. (Pubitemid 351905857)
27. Shippenberg TS, G. K. (2002) Recent advances in animal models of drug addiction and alcoholism, in Neuropsychopharmacology: The Fifth Generation of Progress (KL Davis, D. C.; JT Coyle, C Nemeroff, Ed.), pp 1381-1397, Lippincott Williams and Wilkins, Philadelphia.
28. Carlezon, W. A.; Jr.; Chartoff, E. H. (2007) Intracranial self-stimulation (ICSS) in rodents to study the neurobiology of motivation, Nat Protoc 2, 2987-2995.
29. Ahmed, S. H.; Koob, G. F. (1998) Transition from moderate to excessive drug intake: change in hedonic set point, Science 282, 298-300. (Pubitemid 28487203)
30. Ahmed, S. H.; Walker, J. R.; Koob, G. F. (2000) Persistent increase in the motivation to take heroin in rats with a history of drug escalation, Neuropsychopharmacology 22, 413-421. (Pubitemid 30105769)
31. Roberts, A. J.; Heyser, C. J.; Cole, M.; Griffin, P.; Koob, G. F. (2000) Excessive ethanol drinking following a history of dependence: animal model of allostasis, Neuropsychopharmacology 22, 581-594. (Pubitemid 30219402)
32. Breese, G. R.; Chu, K.; Dayas, C. V.; Funk, D.; Knapp, D. J.; Koob, G. F.; Le, D. A.; ODell, L. E.; Overstreet, D. H.; Roberts, A. J.; Sinha, R.; Valdez, G. R.; Weiss, F. (2005) Stress enhancement of craving during sobriety: a risk for relapse, Alcohol Clin Exp Res 29, 185-195. (Pubitemid 40250507)
33. Kitamura, O.; Wee, S.; Specio, S. E.; Koob, G. F.; Pulvirenti, L. (2006) Escalation of methamphetamine self-administration in rats: a dose-effect function, Psychopharmacology (Berl) 186, 48-53. (Pubitemid 43668310)
34. ODell, L. E.; Chen, S. A.; Smith, R. T.; Specio, S. E.; Balster, R. L.; Paterson, N. E.; Markou, A.; Zorrilla, E. P.; Koob, G. F. (2007) Extended access to nicotine self-administration leads to dependence: Circadian measures, withdrawal measures, and extinction behavior in rats, J Pharmacol Exp Ther 320, 180-193. (Pubitemid 46025733)
35. Edwards, S.; Graham, D. L.; Bachtell, R. K.; Self, D. W. (2007) Region-specifi c tolerance to cocaine-regulated cAMP-dependent protein phosphorylation following chronic self-administration, Eur J Neurosci 25, 2201-2213. (Pubitemid 46581745)
36. Self, D. W. (1998) Neural substrates of drug craving and relapse in drug addiction, Ann Med 30, 379-389. (Pubitemid 28416528)
37. Shaham, Y.; Shalev, U.; Lu, L.; De Wit, H.; Stewart, J. (2003) The reinstatement model of drug relapse: history, methodology and major fi ndings, Psychopharmacology (Berl) 168, 3-20. (Pubitemid 36851158)
38. Miczek, K. A.; Yap, J. J.; Covington, H. E.; 3rd. (2008) Social stress, therapeutics and drug abuse: preclinical models of escalated and depressed intake, Pharmacol Ther 120, 102-128.
39. Callahan, L. B.; Tschetter, K. E.; Ronan, P. J. (2007) Diffi culties associated with the cocaine conditioned place preference (CPP) test using rats, in Society for Neuroscience Abstracts, San Diego.
40. Markou, A.; Weiss, F.; Gold, L. H.; Caine, S. B.; Schulteis, G.; Koob, G. F. (1993) Animal models of drug craving, Psychopharmacology (Berl) 112, 163-182. (Pubitemid 23278275)
41. Tiffany, S. T.; Carter, B. L.; Singleton, E. G. (2000) Challenges in the manipulation, assessment and interpretation of craving relevant variables, Addiction 95 Suppl 2, S177-187. (Pubitemid 30650381)
42. JF Cryan, C. S.; TG Dinan, F Borsini. (2008) Developing more effi cacious antidepressant medication: improving and aligning preclinical and clinical assessment tools. in Animal and Translational Models for CNS Drug Discovery (RA McArthur, F Borsini, Ed.), Elsevier, Amsterdam.
43. Levinson, D. F. (2006) The genetics of depression: a review, Biol Psychiatry 60, 84-92.
44. Krishnan, V.; Nestler, E. J. (2008) The molecular neurobiology of depression, Nature 455, 894-902.
45. Wurtman, R. J. (2005) Genes, stress, and depression, Metabolism 54, 16-19.
46. Moller, H. J. (2003) Suicide, suicidality and suicide prevention in affective disorders, Acta Psychiatr Scand Suppl, 73-80.
47. Moreau, J. L. (1997) Reliable monitoring of hedonic defi cits in the chronic mild stress model of depression, Psychopharmacology (Berl) 134, 357-358; discussion 371-357.
48. Willner, P.; Towell, A.; Sampson, D.; Sophokleous, S.; Muscat, R. (1987) Reduction of sucrose preference by chronic unpredictable mild stress, and its restoration by a tricyclic antidepressant, Psychopharmacology (Berl) 93, 358-364. (Pubitemid 17160661)
49. Yu, J.; Liu, Q.; Wang, Y. Q.; Wang, J.; Li, X. Y.; Cao, X. D.; Wu, G. C. (2007) Electroacupuncture combined with clomipramine enhances antidepressant effect in rodents, Neurosci Lett 421, 5-9. (Pubitemid 46899323)
50. Reid, I.; Forbes, N.; Stewart, C.; Matthews, K. (1997) Chronic mild stress and depressive disorder: a useful new model?, Psychopharmacology (Berl) 134, 365-367; discussion 371-367. (Pubitemid 28023410)
51. Muscat, R.; Kyprianou, T.; Osman, M.; Phillips, G.; Willner, P. (1991) Sweetnessdependent facilitation of sucrose drinking by raclopride is unrelated to calorie content, Pharmacol Biochem Behav 40, 209-213.
52. Willner, P.; Muscat, R.; Papp, M. (1992) Chronic mild stress-induced anhedonia: a realistic animal model of depression, Neurosci Biobehav Rev 16, 525-534.
53. Muscat, R.; Willner, P. (1992) Suppression of sucrose drinking by chronic mild unpredictable stress: a methodological analysis, Neurosci Biobehav Rev 16, 507-517.
54. Katz, R. J. (1982) Animal model of depression: pharmacological sensitivity of a hedonic defi cit, Pharmacol Biochem Behav 16, 965-968. (Pubitemid 12081655)
55. Von Frijtag, J. C.; Van den Bos, R.; Spruijt, B. M. (2002) Imipramine restores the longterm impairment of appetitive behavior in socially stressed rats, Psychopharmacology (Berl) 162, 232-238. (Pubitemid 34762281)
56. Duncko, R.; Schwendt, M.; Jezova, D. (2003) Altered glutamate receptor and corticoliberin gene expression in brain regions related to hedonic behavior in rats, Pharmacol Biochem Behav 76, 9-16. (Pubitemid 38366163)
57. Cheeta, S.; Broekkamp, C.; Willner, P. (1994) Stereospecifi c reversal of stress-induced anhedonia by mianserin and its (+)-enantiomer, Psychopharmacology (Berl) 116, 523-528. (Pubitemid 24374257)
58. Rygula, R.; Abumaria, N.; Domenici, E.; Hiemke, C.; Fuchs, E. (2006) Effects of fl uoxetine on behavioral defi cits evoked by chronic social stress in rats, Behav Brain Res 174, 188-192. (Pubitemid 44397187)
59. Rygula, R.; Abumaria, N.; Flugge, G.; Hiemke, C.; Fuchs, E.; Ruther, E.; Havemann- Reinecke, U. (2006) Citalopram counteracts depressive-like symptoms evoked by chronic social stress in rats, Behav Pharmacol 17, 19-29. (Pubitemid 43068381)
60. Casarotto, P. C.; Andreatini, R. (2007) Repeated paroxetine treatment reverses anhedonia induced in rats by chronic mild stress or dexamethasone, Eur Neuropsychopharmacol 17, 735-742. (Pubitemid 47432838)
61. Markou, A.; Koob, G. F. (1991) Postcocaine anhedonia. An animal model of cocaine withdrawal, Neuropsychopharmacology 4, 17-26.
62. I Geller, J. S. (1960) The effect of meprobamate, barbiturates, d-amphetamine and promazine on experimentally-induced confl ict in the rat, Psychopharmacologia 1, 482-491.
63. File, S. E.; Hyde, J. R. (1978) Can social interaction be used to measure anxiety?, Br J Pharmacol 62, 19-24. (Pubitemid 8251893)
64. Archer, J. (1973) Tests for emotionality in rats and mice: a review, Anim Behav 21, 205-235.
65. Dawson, G. R.; Tricklebank, M. D. (1995) Use of the elevated plus maze in the search for novel anxiolytic agents, Trends Pharmacol Sci 16, 33-36.
66. Handley, S. L.; Mithani, S. (1984) Effects of alpha-adrenoceptor agonists and antagonists in a maze-exploration model of fear-motivated behaviour, Naunyn Schmiedebergs Arch Pharmacol 327, 1-5. (Pubitemid 14061582)
67. Pellow, S.; Chopin, P.; File, S. E.; Briley, M. (1985) Validation of open:closed arm entries in an elevated plus-maze as a measure of anxiety in the rat, J Neurosci Methods 14, 149-167. (Pubitemid 16239568)
68. Pellow, S.; File, S. E. (1986) Anxiolytic and anxiogenic drug effects on exploratory activity in an elevated plus-maze: a novel test of anxiety in the rat, Pharmacol Biochem Behav 24, 525-529. (Pubitemid 16145187)
69. Handley, S. L.; McBlane, J. W. (1993) An assessment of the elevated X-maze for studying anxiety and anxiety-modulating drugs, J Pharmacol Toxicol Methods 29, 129-138. (Pubitemid 23193181)
70. M Reibaud, A. B. (1993) Evolution of putative anxiolytics in the elevated plus-maze, in Paradigms for the Study of Behavior (Conn, M.; Ed.), pp 230-239, Academic Press, San Diego.
71. Gorman, A. L.; Dunn, A. J. (1993) Betaadrenergic receptors are involved in stressrelated behavioral changes, Pharmacol Biochem Behav 45, 1-7.
72. JS Andrews, C. B. (1993) Procedures to identify anxiolytic or anxiogenic agents, in Behavioral Neuroscience: A Practical Approach (Sahgal, A.; Ed.), pp 37-54, IRL Press, Oxford.
73. Korte, S. M.; Korte-Bouws, G. A.; Bohus, B.; Koob, G. F. (1994) Effect of corticotropin- releasing factor antagonist on behavioral and neuroendocrine responses during exposure to defensive burying paradigm in rats, Physiol Behav 56, 115-120. (Pubitemid 24223349)
74. Bowers, R. L.; Herzog, C. D.; Stone, E. H.; Dionne, T. J. (1992) Defensive burying following injections of cholecystokinin, bombesin, and LiCl in rats, Physiol Behav 51, 969-972.
75. Korte, S. M.; Bohus, B. (1990) The effect of ipsapirone on behavioural and cardiac responses in the shock-probe/defensive burying test in male rats, Eur J Pharmacol 181, 307-310. (Pubitemid 20185907)
76. CL Broekkamp, F. J. (1989) The relationship between various animal models of anxiety, fearrelated psychiatric symptoms and response to serotonergic drugs, in Behavioral Pharmacology of 5-HT (P Bevan, R. C.; T Archer, Ed.), pp 321-325, Erlbaum, Hillsdale.
77. Feder, A.; Nestler, E. J.; Charney, D. S. (2009) Psychobiology and molecular genetics of resilience, Nat Rev Neurosci 10, 446-457.
78. Harro, J. (2010) Inter-individual differences in neurobiology as vulnerability factors for affective disorders: implications for psychopharmacology, Pharmacol Ther 125, 402-422.
79. Litt, M. D.; Cooney, N. L. (1999) Inducing craving for alcohol in the laboratory, Alcohol Res Health 23, 174-178.
80. Mason, B. J.; Light, J. M.; Williams, L. D.; Drobes, D. J. (2009) Proof-of-concept human laboratory study for protracted abstinence in alcohol dependence: effects of gabapentin, Addict Biol 14, 73-83.
81. Epstein, D. H.; Preston, K. L. (2003) The reinstatement model and relapse prevention: a clinical perspective, Psychopharmacology (Berl) 168, 31-41. (Pubitemid 36851160)
82. Koob, G. F.; Kenneth Lloyd, G.; Mason, B. J. (2009) Development of pharmacotherapies for drug addiction: a Rosetta stone approach, Nat Rev Drug Discov 8, 500-515.
83. GA Marlatt, J. G. (1985) Relapse Prevention, Guilford Press, New York.
84. Mason, B. J.; Light, J. M.; Escher, T.; Drobes, D. J. (2008) Effect of positive and negative affective stimuli and beverage cues on measures of craving in non treatment-seeking alcoholics, Psychopharmacology (Berl) 200, 141-150.
85. Nestler, E. J.; Barrot, M.; Self, D. W. (2001) DeltaFosB: a sustained molecular switch for addiction, Proc Natl Acad Sci USA 98, 11042-11046. (Pubitemid 32928680)
86. Ulery, P. G.; Rudenko, G.; Nestler, E. J. (2006) Regulation of DeltaFosB stability by phosphorylation, J Neurosci 26, 5131-5142.
87. Carle, T. L.; Ohnishi, Y. N.; Ohnishi, Y. H.; Alibhai, I. N.; Wilkinson, M. B.; Kumar, A.; Nestler, E. J. (2007) Proteasomedependent and -independent mechanisms for FosB destabilization: identifi cation of FosB degron domains and implications for DeltaFosB stability, Eur J Neurosci 25, 3009-3019. (Pubitemid 46888818)
88. Alibhai, I. N.; Green, T. A.; Potashkin, J. A.; Nestler, E. J. (2007) Regulation of fosB and DeltafosB mRNA expression: in vivo and in vitro studies, Brain Res 1143, 22-33. (Pubitemid 46440806)
89. Ulery-Reynolds, P. G.; Castillo, M. A.; Vialou, V.; Russo, S. J.; Nestler, E. J. (2009) Phosphorylation of DeltaFosB mediates its stability in vivo, Neuroscience 158, 369-372.
90. Harris, R. A.; Trudell, J. R.; Mihic, S. J. (2008) Ethanols molecular targets, Sci Signal 1, re7.
91. Martini, L.; Whistler, J. L. (2007) The role of mu opioid receptor desensitization and endocytosis in morphine tolerance and dependence, Curr Opin Neurobiol 17, 556-564.
92. Berger, A. C.; Whistler, J. L. (2010) How to design an opioid drug that causes reduced tolerance and dependence, Ann Neurol 67, 559-569.
93. Littleton, J. (2007) Acamprosate in Alcohol Dependence: Implications of a Unique Mechanism of Action, Journal of Addiction Medicine 1, 115-125.
94. Hollenbeck, P. J.; Bamburg, J. R. (2003) Comparing the properties of neuronal culture systems: a shopping guide for the cell biologist, Methods Cell Biol 71, 1-16.
95. Matteoli, M.; Verderio, C.; Krawzeski, K.; Mundigl, O.; Coco, S.; Fumagalli, G.; De Camilli, P. (1995) Mechanisms of synaptogenesis in hippocampal neurons in primary culture, J Physiol Paris 89, 51-55.
96. Gao, C.; Wolf, M. E. (2007) Dopamine alters AMPA receptor synaptic expression and subunit composition in dopamine neurons of the ventral tegmental area cultured with prefrontal cortex neurons, J Neurosci 27, 14275-14285.
97. Fitzgerald, L. W.; Ortiz, J.; Hamedani, A. G.; Nestler, E. J. (1996) Drugs of abuse and stress increase the expression of GluR1 and NMDAR1 glutamate receptor subunits in the rat ventral tegmental area: common adaptations among cross-sensitizing agents, J Neurosci 16, 274-282.
98. Wolf, M. E. (1998) The role of excitatory amino acids in behavioral sensitization to psychomotor stimulants, Prog Neurobiol 54, 679-720. (Pubitemid 28137703)
99. Saal, D.; Dong, Y.; Bonci, A.; Malenka, R. C. (2003) Drugs of abuse and stress trigger a common synaptic adaptation in dopamine neurons, Neuron 37, 577-582. (Pubitemid 36262980)